Kymera's KT-621 Phase 1 Data in Japanese Adults Consistent, Supports Global Advancement
KYMR has more than doubled off its 52-week low of $36.65.
Summary
Kymera Therapeutics presented positive Phase 1 data for its lead immunology drug, KT-621, in healthy Japanese adults. The study demonstrated a favorable safety profile, rapid and sustained STAT6 degradation, and consistent pharmacokinetic and pharmacodynamic results compared to prior studies. This consistency across populations de-risks the drug's profile and supports its global development, building on the Fast Track designation KT-621 received in April. Phase 2b data for atopic dermatitis is anticipated by mid-2027, with asthma data expected by late 2027.
At the time of this announcement, KYMR was trading at $82.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8B. The 52-week trading range was $36.65 to $103.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.